Please assess the completion status of the following clinical trial:

Trial Title: Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent MUST be obtained prior to participation in the study~* Study eye is diagnosed with nAMD and deemed to be eligible for intravitreal injection at the discretion of the Investigator~Exclusion Criteria:~* Concomitant conditions or ocular disorders in the study eye at screening which may cause safety concerns on the judgement of the investigator~* Any active intraocular or periocular or systemic infection or active intraocular inflammation at Baseline~* Treatment with any ocular intravitreal injection in the study eye within the past 7 half lives prior to Baseline~* Intraocular surgery, prior long-acting therapeutic agent, or ocular drug release device implantation (approved or investigational) in the study eye any time during the past 3 months prior to Baseline~* Diagnosis of ECG abnormalities including:~* Clinically significant cardiac arrhythmias, e.g., atrial fibrillation, sustained ventricular tachycardia, and clinically significant second or third degree AV block without a pacemaker~* Familial long QT syndrome or known family history of Torsades de Pointes~* Resting heart rate \< 50 or \> 90 bpm at screening~* Resting QTcF ≥ 450 ms (male) or ≥ 460 ms (female) at screening~* Use of concomitant medications that are classified as known risk, conditional risk or possible risk to prolong QT/QTc interval within 7 half-lives prior to Baseline~* History of stroke (including transient ischemic attack, reversible ischemic neurological deficit, prolonged reversible ischemic neurological deficit) or myocardial infarction (ST or non-ST elevation myocardial infarction) at any time prior to baseline~* Chronic kidney disease as determined as a CrCL at screening of \< 60 ml/min/1.73 m2 as determined by the MDRD formula~* Uncontrolled high blood pressure defined as a systolic value ≥ 140 mmHg or diastolic value ≥ 90 mmHg at screening or baseline~* Systemic anti-VEGF therapy during the 6-month period prior to baseline~* Electrolyte disturbances determined as out of normal range sodium, potassium or calcium serum concentrations at screening~* Concomitant intake of long-acting muscarinic antagonist (LAMA)/ long-acting beta adrenergic (LABA) combination therapy~* History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar classes as assessed by the investigator~* Use of systemic or ocular (including intravitreal) investigational drugs within 7 half-lives of baseline, (or within 30 days/until the expected pharmacodynamic effect has returned to baseline), whichever is longer or longer if required by local regulations (observational clinical studies solely involving over-the-counter vitamins, supplements, or diets are not exclusionary)~* Pregnant or nursing (lactating) women

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RTH258 (Type: EXPERIMENTAL): Intravitreal injection

Based on this trial design, predict the completion outcome and termination type (if applicable).